Related Experiment Videos
Acrocyanosis induced by interferon alpha(2a)
A Campo-Voegeli1, T Estrach, R M Marti
1Department of Dermatology, Hospital Clinic i Provincial de Barcelona, España.
Dermatology (Basel, Switzerland)
|June 11, 1998
Summary
A woman experienced acrocyanosis during interferon alpha-2a treatment for mycosis fungoides. This side effect, linked to elevated antinuclear antibody titers, highlights potential autoimmune risks of interferon therapy.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Mycosis fungoides is a type of cutaneous T-cell lymphoma.
- Interferon therapy is used for certain cancers and viral infections.
- Autoimmune side effects are known complications of long-term interferon treatment.
Observation:
- A 56-year-old woman with mycosis fungoides developed acrocyanosis.
- Acrocyanosis recurred upon initiation of interferon alpha-2a and resolved upon discontinuation.
- Immunological studies revealed elevated antinuclear antibody (ANA) titers and immune complexes during acrocyanosis.
Findings:
- This case presents acrocyanosis as a previously undescribed side effect of interferon alpha-2a.
- The patient's symptoms correlated with immunological markers of autoimmunity.
- Interferon-induced autoimmunity may manifest in various ways, including peripheral vascular changes.
Implications:
- Clinicians should consider acrocyanosis as a potential adverse effect of interferon alpha-2a, particularly in patients with underlying autoimmune risk factors.
- Further research is warranted to elucidate the mechanisms linking interferon therapy to acrocyanosis and other autoimmune phenomena.
- This finding expands the spectrum of known interferon-related side effects and emphasizes the importance of vigilant monitoring for autoimmune complications during treatment.